COMPARISON OF ORAL SECNIDAZOLE AND CLINDAMYCIN IN TREATMENT OF BACTERIAL VAGINOSIS by Dr. Maida Khan, Dr Hafiz Hasan Fazal Sheikh, Dr. Sana Khalid
IAJPS 2018, 05 (12), 14409-14411                     Maida Khan et al                    ISSN 2349-7750 
 
 
 
w w w . i a j p s . c o m  
 
Page 14409 
 
        CODEN [USA]: IAJPBB                        ISSN: 2349-7750 
 
  INDO AMERICAN JOURNAL OF 
 PHARMACEUTICAL SCIENCES 
                              
Available online at: http://www.iajps.com                                  Research Article 
COMPARISON OF ORAL SECNIDAZOLE AND 
CLINDAMYCIN IN TREATMENT OF BACTERIAL VAGINOSIS 
1Dr. Maida Khan, 2Dr Hafiz Hasan Fazal Sheikh, 3Dr. Sana Khalid  
1Mayo Hospital Lahore 
2Medical Officer, DHQ Hospital Hafizabad 
3Combined Military Hospital Sialkot 
Abstract: 
Objective: To evaluate the efficacy of using secnidazole as single per oral dose in comparison with clindamycin for 
treating bacterial vaginosis. 
Method: The study design followed in this research was double blind randomized controlled trial. It was conducted 
at Shifa foundation, Community Health Centre over period of 2 years and 11 months from March 2012 to February 
2015. Informed consent was taken from all cases and diagnosis was confirmed by physical examination and 
presence of milky discharge was confirmed, followed by confirmation on microscopy by looking for clue cells and 
positive amine test. Exclusion criteria was pregnancy, immunocompromised state or diabetic women. Doctor, 
patient and pharmacist blinding was ensured. Sample was divided into two groups, group 1 was given pack 1 
medicine containing clindamycin and oral placebo while group 2 was given pack 2 which had 2g secnidazole in it 
along with placebo topical vaginal preparation. Recovery criteria was reversal of two out of following three 
symptoms i.e. milky vaginal discharge, negative amine test, normal Nugent score after 15 days of treatment 
initiation. 
Results: 96% cases who were on clindamycin treatment recovered on 15th day while only 23% patients recovered by 
taking secnidazole orally. 
Key Words: vaginal clindamycin, bacterial vaginosis, oral secnidazole, treatment. 
Corresponding author:  
Maida Khan, 
Mayo Hospital, Lahore. 
 
 
 
 
Please cite this article in press Maida Khan et al., Comparison Of Oral Secnidazole And Clindamycin In 
Treatment Of Bacterial Vaginosis., Indo Am. J. P. Sci, 2018; 05(12). 
 
 
 
 
 
  
QR code 
 
 
 
 
IAJPS 2018, 05 (12), 14409-14411                     Maida Khan et al                    ISSN 2349-7750 
 
 
 
w w w . i a j p s . c o m  
 
Page 14410 
INTRODUCTION: 
A polymicrobial vaginal infection which leads to 
change in normal vaginal flora. Normal commensals 
in vagina are lactobacilli such as L crispatus which 
keeps the vaginal pH in acidic range by secreting 
lactic acid and hence prevent from vaginal infections. 
The culprit organisms for bacterial vaginosis include 
G vaginalis, Prevotella, Bacteroides, Mobiluncus, 
ureaplasma and Mycoplasma1.The complications 
associated with bacterial vaginosis include reduced 
fertility rate, PID (Pelvic inflammatory disease), 
Preterm labor, premature placental membranes 
rupture1. 4It is one of the commonest STD (sexually 
transmitted disease).  
 
2Bacterial vaginosis is highly prevalent disease 
amongst pregnant women. 3Amsel criteria is used for 
its diagnosis; pH less than five, milky white 
discharge, amine order after mixing with base, clue 
cells on gram staining. 3 out 4 positive points 
confirm presence of disease. The clue cells make the 
most reliable diagnostic marker with sensitivity and 
specificity of 93% and 70%, respectively. 
 
5Metronidazole is commonly used for treating 
bacterial vaginosis and its effectiveness has already 
been approved. The clindamycin as effective 
treatment against bacterial vaginosis is in use across 
the globe. Its route of administration doesn’t change 
the effectivity in significant range. Secnidazole 
2grams orally in a single dose has been tested and 
approved as effective treatment against bacterial 
vaginosis amongst asymptomatic patients and 
uncomplicated cases. Clindamycin is a better 
treatment option for A vaginae, G vaginalis, M spp. 
However, Prevotella, Peptinophilus, Bacteroides spp. 
Shows positive response to metronidazole as 
compared to clindamycin6. This research aims at 
studying the effect of secnidazole in symptomatic 
patients with bacterial vaginosis.  
 
METHODOLOGY: 
The study design followed in this research was 
double blind randomized controlled trial. It was 
conducted at Shifa foundation, Community Health 
Centre over period of 2 years and 11 months from 
March 2012 to February 2015. No ethical issue 
certificate was taken for ethical committee. Informed 
consent was taken from all cases. Patients presented 
with complaint of milky vaginal discharge were 
enrolled in study and were examined and investigated 
for the confirmation of diagnosis. Pelvic examination 
was done and secretions were collected after 
speculum examination, then microscopy was 
performed.  Those patients with vaginal pH more 
than 4 and clue cells on microscopy were enrolled in 
study and labelled confirmed case. Exclusion criteria 
was pregnancy, immunocompromised or diabetic 
females.  
 
The patients were divided into group 1 and 2 and 
medicines were divided into two packets, each pack 
was labelled as 1 or 2 with different packet content. 
Blinding of physician, patient and pharmacist was 
done about medicine packet content. Packet 1 had 
clindamycin and oral placebo in it while while 2 
grams secnidazole along with placebo vaginal cream 
was present in the other packet. Packet 1 was given to 
group 1 while packet 2 was given to group 2. All 
patients were re-evaluated after 15 days.  
SPPS 21 was brought in use to analyse data. 
Percentages and frequencies were used to present 
qualitative data. McNemar’s test was used to 
compare the outcome. P value <0.05 was considered 
significant. Despite of telephonic contact with the 
patients, ten patients were lost to follow up. 
 
RESULTS: 
192 patients were enrolled and were divided into 
group 1 and 2 randomly. Both groups were given 
respective medicine packets. 182 patients out of the 
total sample remained till the 15th day follow-up, rest 
of them were lost to follow-up despite of repeated 
telephonic contact. Each group contained 91 patients 
and were given clindamycin and secnidazole, 
respectively. Pelvic examination of all cases was 
done. 74 patients i.e. 81% showed positive amine test 
in group 1, while 82 patients i.e. 90% were positive 
in secnidazole group. Clue cells were positive in 91% 
and 92% in both groups respectively as shown in 
table-1. 
 
The statistics of 15th day follow up in both groups 
were as follow. In group 1, who received 
clindamycin and placebo oral 84 patients (92%) were 
discharge free, 87 (96%) patients had negative clue 
cells and amine test. Statistics of secnidazole 
receiving group were 15 (16%) patients were 
discharge free, 63 (69%) patients were still amine test 
positive, clue cells were detected in 77% i.e. 70 
patients, respectively which shows failure to 
treatment with secnidazole in group 2 as compared to 
clindamycin in group 1 as shown in table-1. 
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Table-1: Amsel criteria before and after treatment. 
parameters Before clindamycin After 15 days of 
clindamycin 
Before secnidazole After 15 days of 
secnidazole 
Clue cells 
Vaginal discharge 
Amine test 
p-value 
83 (91%) 
91 (100%) 
74 (81%) 
Less than 0.0001 
4 (4)% 
7 (8%) 
4 (4%) 
84 (92%) 
91 (100%) 
82 (90%) 
Less than 0.0001 
70 (77%) 
76 (84%) 
63 (69%) 
 
 
Thus there was statistically significant difference in both groups and clindamycin was found to be a better treatment 
option for bacterial vaginosis in comparison with secnidazole. 
 
DISCUSSION: 
6,7,8Multiple drugs have been tested so far to treat the 
bacterial vaginosis. The most commonly used drugs 
are clindamycin in either topical or systemc form but 
the route of administration doesn’t affect the drug 
efficacy in treating BV. Secnidazole, like 
metronidazole has been tested and its use for treating 
asymptomatic BV or complication free disease has 
been approved. 2 gram single dose secnidazole and 
2% clindamycin was given to patients by randomly 
allocating into two groups. The double blind 
randomized controlled trial was conducted in this 
regard. 
Similar researches have been done by many other 
authors too. But due to less data available in 
Pakistani population the rsearchers aim to study its 
role by targeting local Pakistani population.  
9Karthick A has studied the use of sustained release 
secnidazole gels for curing BV. While the drug safety 
and major side effects associated with secnidazole 
treatment were studied by 10Darpo B, et al. and 
concluded the least cardiac side effects of understudy 
drug.  
7Nyirjesy P, et al. conducted a study which was 
published in 2018. In his research he concluded the 
effective use of secnidazole for treating the BV and 
also he studied and approved its use in preventing 
serious complications. In already complicated BV 
patients the secnidazole benefits are not statistically 
significant. However, more research work is needed 
to bring the use of secnidazole into a better 
conclusion, so that STDs can be effectively and 
timely controlled by using multiple regimens. 
 
CONCLUSION: 
The effect of clindamycin in treating bacterial 
vaginosis is better than single dose oral secnidazole.  
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